SARS-CoV-2 sero-immunity and quality of life in children and adolescents in relation to infections and vaccinations: the IMMUNEBRIDGE KIDS cross-sectional study, 2022.

Adolescent Child Humans Child, Preschool Quality of Life SARS-CoV-2 Cross-Sectional Studies COVID-19 / epidemiology Seroepidemiologic Studies Antibodies, Viral Vaccination
Children and adolescents Omicron Quality of life SARS-CoV-2 Seroprevalence

Journal

Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 21 02 2023
accepted: 13 05 2023
medline: 23 10 2023
pubmed: 7 6 2023
entrez: 6 6 2023
Statut: ppublish

Résumé

The study evaluates the effects on sero-immunity, health status and quality of life of children and adolescents after the upsurge of the Omicron variant in Germany. This multicenter cross-sectional study (IMMUNEBRIDGE Kids) was conducted within the German Network University Medicine (NUM) from July to October 2022. SARS-CoV-2- antibodies were measured and data on SARS-CoV-2 infections, vaccinations, health and socioeconomic factors as well as caregiver-reported evaluation on their children's health and psychological status were assessed. 497 children aged 2-17 years were included. Three groups were analyzed: 183 pre-schoolchildren aged 2-4 years, 176 schoolchildren aged 5-11 years and 138 adolescents aged 12-18 years. Positive antibodies against the S- or N-antigen of SARS-CoV-2 were detected in 86.5% of all participants (70.0% [128/183] of pre-schoolchildren, 94.3% of schoolchildren [166/176] and 98.6% of adolescents [136/138]). Among all children, 40.4% (201/497) were vaccinated against COVID-19 (pre-schoolchildren 4.4% [8/183], schoolchildren 44.3% [78/176] and adolescents 83.3% [115/138]). SARS-CoV-2 seroprevalence was lowest in pre-school. Health status and quality of life reported by the parents were very positive at the time of the survey (Summer 2022). Age-related differences on SARS-CoV-2 sero-immunity could mainly be explained by differences in vaccination rates based on the official German vaccination recommendations as well as differences in SARS-CoV-2 infection rates in the different age groups. Health status and quality of life of almost all children were very good independent of SARS-CoV-2 infection and/or vaccination. German Registry for Clinical Trials Identifier Würzburg: DRKS00025546 (registration: 11.09.2021), Bochum: DRKS00022434 (registration:07.08.2020), Dresden: DRKS 00022455 (registration: 23.07.2020).

Identifiants

DOI: 10.1007/s15010-023-02052-5 PMID: 37280412 PMC: PMC10243264
pubmed: 37280412
doi: 10.1007/s15010-023-02052-5
pii: 10.1007/s15010-023-02052-5
pmc: PMC10243264
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1531-1539

Subventions

Organisme : Bundesministerium für Bildung und Forschung
ID : 01KX2121
Organisme : Freistaat Sachsen
ID : paedSaxCoviDD
Organisme : Bavarian State Ministry of Health and Care and the Bavarian Health and Food Safety Authority
ID : K3-2484-PN 22-38-V3-D28504/2022

Investigateurs

Johannes Forster (J)
Oliver Kurzai (O)
Franziska Pietsch (F)
Elena Hick (E)
Katharina Hecker (K)
Thomas Lücke (T)
Anna Hoffmann (A)
Michaela Schwarzbach (M)
Jakob Höppner (J)
Denisa Drinka (D)
Jakob Armann (J)
Judith Blankenburg (J)
Uta Falke (U)
Josephine Schneider (J)
Veronika Jäger (V)
Viktoria Rücker (V)
Manuela Harries (M)
Max Hassenstein (M)
Maren Dreier (M)
Isabell von Holt (I)
Axel Budde (A)
Marc-André Kurosinski (MA)
Antonia Bartz (A)
Gunnar Brandhorst (G)
Melanie Brinkmann (M)
Kathrin Budde (K)
Marek Deckena (M)
Marc Fenzlaff (M)
Olga Hovardovska (O)
Katja Kehl (K)
Mirjam Kohls (M)
Stefan Krüger (S)
Kristin Meyer-Schlinkmann (K)
Patrick Ottensmeyer (P)
Jens-Peter Reese (JP)
Daniel Rosenkranz (D)
Nicole Rübsamen (N)
Mario Schattschneider (M)
Christin Schäfer (C)
Simon Schlinkert (S)
Kai Schulze-Wundling (K)
Stefan Störk (S)
Carsten Tiemann (C)
Henry Völzke (H)
Theresa Winter (T)
Peter Heuschmann (P)
Matthias Nauck (M)

Informations de copyright

© 2023. The Author(s).

Références

Robert Koch Institut: Wöchentlicher Lagebericht des RKI zur Coronavirus-Krankheit-2019 (COVID-19). https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/Wochenbericht/Wochenbericht_2021-12-30.pdf?__blob=publicationFile . Accessed 31.10.2022.
Edward PR, Lorenzo-Redondo R, Reyna ME, Simons LM, Hultquist JF, Patel AB, et al. Severity of illness caused by severe acute respiratory syndrome coronavirus 2 variants of concern in children: a single-center retrospective cohort study. J Pediatric Infect Dis Soc. 2022;11:440–7. https://doi.org/10.1093/jpids/piac068 .
doi: 10.1093/jpids/piac068 pubmed: 35924454 pmcid: 9384683
Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179:1029–46. https://doi.org/10.1007/s00431-020-03684-7 .
doi: 10.1007/s00431-020-03684-7 pubmed: 32424745 pmcid: 7234446
Ravens-Sieberer U, Kaman A, Erhart M, Devine J, Schlack R, Otto C. Impact of the COVID-19 pandemic on quality of life and mental health in children and adolescents in Germany. Eur Child Adolesc Psychiatry. 2022;31:879–89. https://doi.org/10.1007/s00787-021-01726-5 .
doi: 10.1007/s00787-021-01726-5 pubmed: 33492480
Cloete J, Kruger A, Masha M, du Plessis NM, Mawela D, Tshukudu M, et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B. 1.1.5.29) variant wave in South Africa: a multicentre observational study. Lancet Child Adolesc. 2022;6:294–302. https://doi.org/10.1016/S2352-4642(22)00027-X .
doi: 10.1016/S2352-4642(22)00027-X
Ott R, Achenbach P, Ewald DA, Friedl N, Gemulla G, Hubmann M, et al. SARS-CoV-2 Seroprevalence in preschool and school-age children-population screening findings From January 2020 to June 2022. Dtsch Arztebl Int. 2022. https://doi.org/10.3238/arztebl.m2022.0355 . (Forthcoming).
doi: 10.3238/arztebl.m2022.0355 pubmed: 36474342 pmcid: 9749843
Engels GHK, Forster J, et al. High seroprevalence of SARS-CoV-2 in preschool children in July 2022—a cross-sectional data collection in day-care centers. Dtsch Arztebl Int. 2022. https://doi.org/10.3238/arztebl.m2022.0345 .
doi: 10.3238/arztebl.m2022.0345 pubmed: 36700368 pmcid: 9884839
Armann JPBJ, Czyborra P, et al. SARS-CoV-2 immunity gap among schoolchildren and teachers in the summer of 2022. Dtsch Arztebl Int. 2022. https://doi.org/10.3238/arztebl.m2022.0307 .
doi: 10.3238/arztebl.m2022.0307 pubmed: 36727650
Zaballa M-E, Perez-Saez J, de Mestral C, Pullen N, Lamour J, Turelli P, et al. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA2 wave in Geneva, Switzerland. medRxiv. 2022. https://doi.org/10.1101/2022.07.27.22278126 .
doi: 10.1101/2022.07.27.22278126
Mari A, Garancini N, Barcellini L, Alberti LF, Gaia P, Amendola A, et al. SARS-CoV-2 seroprevalence among school-age children in Milan: how has it changed with the fourth pandemic wave? Pediatr Infect Dis J. 2022;41:e344–5.
doi: 10.1097/INF.0000000000003583 pubmed: 35622423 pmcid: 9281415
Centre HHPS. Seroprevalence of antibodies to SARS-CoV-2in children aged 1–12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1. 2022.
Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection severity in children under 5 years old before and after Omicron emergence in the USA. medRxiv. 2022;600:577. https://doi.org/10.1101/2022.01.12.22269179 .
doi: 10.1101/2022.01.12.22269179
Marks KJ, Whitaker M, Agathis NT, Anglin O, Milucky J, Patel K, et al. Hospitalization of infants and children aged 0–4 years with laboratory-confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:429–36. https://doi.org/10.15585/mmwr.mm7111e2 .
doi: 10.15585/mmwr.mm7111e2 pubmed: 35298458 pmcid: 8942304
Doenhardt M, Gano C, Sorg AL, Diffloth N, Tenenbaum T, von Kries R, et al. Burden of pediatric SARS-CoV-2 hospitalizations during the Omicron wave in Germany. Viruses. 2022. https://doi.org/10.3390/v14102102 .
doi: 10.3390/v14102102 pubmed: 36298657 pmcid: 9607436
Butt AA, Dargham SR, Loka S, Shaik RM, Chemaitelly H, Tang P, et al. Coronavirus disease 2019 disease severity in children infected with the omicron variant. Clin Infect Dis. 2022;75:e361–7. https://doi.org/10.1093/cid/ciac275 .
doi: 10.1093/cid/ciac275 pubmed: 35404391
Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Risk of infection and hospitalization among vaccinated and unvaccinated Children and adolescents in New York after the emergence of the omicron variant. J Am Med Assoc. 2022. https://doi.org/10.1001/jama.2022.7319 .
doi: 10.1001/jama.2022.7319
Vygen-Bonnet SKJ, Armann J, et al. Beschluss der STIKO zur 9 Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung. Epid Bull. 2021. https://doi.org/10.25646/8942.2 .
doi: 10.25646/8942.2
Impfkommission S. Beschluss der STIKO zur 22 Aktualisierung der COVID-19-Impfempfehlung. Epid Bull. 2022;40:3–20. https://doi.org/10.25646/10656 .
doi: 10.25646/10656
Ständige Impfkommission. Beschluss der STIKO zur 20. Aktualisierung der COVID-19-Impfempfehlung Epid Bull. 2022; https://doi.org/10.25646/10076.2 .
Forster J, Streng A, Rudolph P, Rucker V, Wallstabe J, Timme S, et al. Feasibility of SARS-CoV-2 surveillance testing among children and childcare workers at German day care centers a nonrandomized controlled trial. JAMA Netw Open. 2022;5:e2142057. https://doi.org/10.1001/jamanetworkopen.2021.42057 .
doi: 10.1001/jamanetworkopen.2021.42057 pubmed: 34982157 pmcid: 8728621
Engels G, Forster J, Streng A, Rucker V, Rudolph P, Pietsch F, et al. Acceptance of different self-sampling methods for semiweekly SARS-CoV-2 testing in asymptomatic children and childcare workers at german day care centers a nonrandomized controlled trial. JAMA Netw Open. 2022;5:e2231798. https://doi.org/10.1001/jamanetworkopen.2022.31798 .
doi: 10.1001/jamanetworkopen.2022.31798 pubmed: 36107424 pmcid: 9478779
Köhler L, Rigby M. Indicators of children’s development: considerations when constructing a set of national child health indicators for the European union. Child Care Health Dev. 2003;29:551–8. https://doi.org/10.1046/j.1365-2214.2003.00375.x .
doi: 10.1046/j.1365-2214.2003.00375.x pubmed: 14616913
Forrest CB, Bevans KB, Pratiwadi R, Moon J, Teneralli RE, Minton JM, et al. Development of the PROMIS
doi: 10.1007/s11136-013-0581-8 pubmed: 24264804
Ravens-Sieberer U, Gosch A, Rajmil L, Erhart M, Bruil J, Power M, et al. The KIDSCREEN-52 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries. Value Health. 2008;11:645–58. https://doi.org/10.1111/j.1524-4733.2007.00291.x .
doi: 10.1111/j.1524-4733.2007.00291.x pubmed: 18179669
Otto C, Reiss F, Voss C, Wüstner A, Meyrose AK, Hölling H, et al. Mental health and well-being from childhood to adulthood: design, methods and results of the 11-year follow-up of the BELLA study. Eur Child Adolesc Psychiatry. 2021;30:1559–77. https://doi.org/10.1007/s00787-020-01630-4 .
doi: 10.1007/s00787-020-01630-4 pubmed: 32918625
Hölling H, Schlack R, Kamtsiuris P, Butschalowsky H, Schlaud M, Kurth BM. Die KiGGS-studie. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 2012;55:836–42. https://doi.org/10.1007/s00103-012-1486-3 .
doi: 10.1007/s00103-012-1486-3 pubmed: 22736165
Skowronski DM, Kaweski SE, Irvine MA, Kim S, Chuang ES, Sabaiduc S, et al. Serial cross-sectional estimation of vaccine and infection-induced SARS-CoV-2 sero-prevalence in children and adults, British Columbia Canada March 2020 to August 2022. Medrxiv. 2022. https://doi.org/10.1101/2022.09.09.22279751 .
doi: 10.1101/2022.09.09.22279751
Ahava MJ, Jarva H, Jääskeläinen AJ, Lappalainen M, Vapalahti O, Kurkela S. Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron variant, Finland. Eur J Clin Microbiol Infect Dis. 2022;41:997–9. https://doi.org/10.1007/s10096-022-04448-x .
doi: 10.1007/s10096-022-04448-x pubmed: 35484359 pmcid: 9049924
Erikstrup C, Laksafoss AD, Gladov J, Kaspersen KA, Mikkelsen S, Hindhede L, et al. Seroprevalence and infection fatality rate of the SARS-CoV-2 omicron variant in Denmark: a nationwide serosurveillance study. Lancet Reg Health Eur. 2022. https://doi.org/10.1016/j.lanepe.2022.100479 .
doi: 10.1016/j.lanepe.2022.100479 pubmed: 35959415 pmcid: 9355516
Castilla J, Lecea Ó, Martín Salas C, Quílez D, Miqueleiz A, Trobajo-Sanmartín C, et al. Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. Eurosurveillance. 2022;27:2200619. https://doi.org/10.2807/1560-7917.ES.2022.27.33.2200619 .
doi: 10.2807/1560-7917.ES.2022.27.33.2200619 pubmed: 35983774 pmcid: 9389855
Lange B, Jäger V, Rücker V, Harries M, Hassenstein M, Dreier M, et al. 2. Interimsanalyse des IMMUNEBRIDGE-Projektes zur Kommunikation von vorläufigen Ergebnissen an das Modellierungsnetz für schwere Infektionskrankheiten. https://zenodo.org/record/7177592#.Y242LdaZOM8 . Accessed 11.11.2022.
Impfquote gegen das Coronavirus in Deutschland nach Altersgruppe. https://de.statista.com/statistik/daten/studie/1258043/umfrage/impfquote-gegen-das-coronavirus-in-deutschland-nach-altersgruppe/ . Accessed 31.10.2022.
https://www.ema.europa.eu/en/news/ema-recommends-approval-comirnaty-spikevax-covid-19-vaccines-children-6-months-age . Accessed 09.11.2022.
Koch JPV, Vygen-Bonnet S, et al. Wissenschaftliche Begründung der STIKO für die COVID-19-Impf-empfehlung für Kinder im Alter von 6 Monaten bis 4 Jahren sowie zur Anpassung der COVID-19-Impf-empfehlung für Kinder im Alter von 5–11 Jahre. Epid Bull. 2022;46:22–47.
Meherali S, Punjani N, Louie-Poon S, Abdul Rahim K, Das JK, Salam RA, et al. Mental health of children and adolescents amidst COVID-19 and past pandemics: a rapid systematic review. Int J Environ Res Public Health. 2021. https://doi.org/10.3390/ijerph18073432 .
doi: 10.3390/ijerph18073432 pubmed: 34948829 pmcid: 8701118
Oliveira JMD, Butini L, Pauletto P, Lehmkuhl KM, Stefani CM, Bolan M, et al. Mental health effects prevalence in children and adolescents during the COVID-19 pandemic: a systematic review. Worldviews Evid Based Nurs. 2022;19:130–7. https://doi.org/10.1111/wvn.12566 .
doi: 10.1111/wvn.12566 pubmed: 35229967 pmcid: 9115455
Elharake JA, Akbar F, Malik AA, Gilliam W, Omer SB. Mental health impact of COVID-19 among children and college students: a systematic REVIEW. Child Psychiat Hum D. 2022. https://doi.org/10.1007/s10578-021-01297-1 .
doi: 10.1007/s10578-021-01297-1
Kauhanen L, Yunus WMAWM, Lempinen L, Peltonen K, Gyllenberg D, Mishina K, et al. A systematic review of the mental health changes of children and young people before and during the COVID-19 pandemic. Eur Child Adoles Psy. 2022. https://doi.org/10.1007/s00787-022-02060-0 .
doi: 10.1007/s00787-022-02060-0

Auteurs

Geraldine Engels (G)

Department of Pediatrics, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

Anna-Lisa Oechsle (AL)

Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, LMU Munich, Haydnstraße 5, 80336, Munich, Germany.

Anne Schlegtendal (A)

Children's Hospital, Ruhr University of Bochum, Alexandrinenstrasse 5, 44791, Bochum, Germany.

Christoph Maier (C)

Children's Hospital, Ruhr University of Bochum, Alexandrinenstrasse 5, 44791, Bochum, Germany.

Sarah Holzwarth (S)

Department of Pediatrics, Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, Fetscherstr. 74, 01307, Dresden, Germany.

Andrea Streng (A)

Department of Pediatrics, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

Berit Lange (B)

Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, 38124, Brunswick, Germany.
German Centre for Infection Research (DZIF), TI BBD, Brunswick, Germany.

Andre Karch (A)

Institute for Epidemiology and Social Medicine, University of Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Germany.

Astrid Petersmann (A)

Institute for Clinical Chemistry and Laboratory Medicine, University Oldenburg, Rahel-Straus-Straße 10, 26133, Oldenburg, Germany.
Institute for Clinical Chemistry and Laboratory Medicine, University of Greifswald, Ferdinand-Sauerbruchstrasse, 17475, Greifwald, Germany.

Hendrik Streeck (H)

Institute of Virology, University Hospital, University of Bonn, Venusberg-Campus 1, Gebäude 63, 53127, Bonn, Germany.
German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Brunswick, Germany.

Sabine Blaschke-Steinbrecher (S)

Emergency Department, University Medical Center Göttingen, Robert-Koch Sr. 40, 37075, Göttingen, Germany.

Christoph Härtel (C)

Department of Pediatrics, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

Horst Schroten (H)

Pediatric Infectious Diseases, Department of Pediatrics, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.

Rüdiger von Kries (R)

Division of Epidemiology, Institute of Social Pediatrics and Adolescent Medicine, LMU Munich, Haydnstraße 5, 80336, Munich, Germany.

Reinhard Berner (R)

Department of Pediatrics, Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, Fetscherstr. 74, 01307, Dresden, Germany.

Johannes Liese (J)

Department of Pediatrics, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.

Folke Brinkmann (F)

Children's Hospital, Ruhr University of Bochum, Alexandrinenstrasse 5, 44791, Bochum, Germany.
Department of Pediatrics, University of Lübeck, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.

Nicole Toepfner (N)

Department of Pediatrics, Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, Fetscherstr. 74, 01307, Dresden, Germany. Nicole.Toepfner@uniklinikum-dresden.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › Enfant d'âge préscolaire › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études séroépidémiologiques › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › SARS-CoV-2 sero-immunity and quality of life...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › SARS-CoV-2 sero-immunity and quality of life...